['early-stage breast carcinoma', 'her-2 positive breast cancer']
['docetaxel + trastuzumab sc + pertuzumab', 'trastuzumab emtansin']

        Inclusion Criteria:

          1. Written informed consent

          2. Patients with breast cancer confirmed by histology, characterized by
             immunohistochemistry for ER, PR, HER2 and proliferation marker

          3. Tumor and blood samples available. HER2 type confirmed by ISH

          4. Age 18 years or older. Elderly patients in condition adequate for planned therapy

          5. Primary breast cancer >20mm in diameter and/or verified lymph node metastases

          6. Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled
             medical or psychiatric disorders

          7. LVEF ≥55%

          8. ECOG performance status 0-1

          9. Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized
             well-defined distant metastases accessible for stereotactic radiotherapy, provided
             that this treatment is available

        Exclusion Criteria:

          1. Distant metastases, including node metastases in the contralateral thoracic region or
             in the mediastinum

          2. Other malignancy diagnosed within the last five years, except for radically treated
             basal or squamous cell carcinoma of the skin or CIS of the cervix

          3. Patients in child-bearing age without adequate contraception

          4. Pregnancy or lactation

          5. Uncontrolled hypertension, heart, liver, kidney related or other medical or
             psychiatric disorders
      